Intra-Cellular Therapies Revenue 2013-2022 | ITCI

Intra-Cellular Therapies annual/quarterly revenue history and growth rate from 2013 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Intra-Cellular Therapies revenue for the quarter ending March 31, 2022 was $0.035B, a 120.41% increase year-over-year.
  • Intra-Cellular Therapies revenue for the twelve months ending March 31, 2022 was $0.103B, a 173.67% increase year-over-year.
  • Intra-Cellular Therapies annual revenue for 2021 was $0.084B, a 267.35% increase from 2020.
  • Intra-Cellular Therapies annual revenue for 2020 was $0.023B, a 37298.36% increase from 2019.
  • Intra-Cellular Therapies annual revenue for 2019 was $0B, a INF% increase from 2018.
Intra-Cellular Therapies Annual Revenue
(Millions of US $)
2021 $84
2020 $23
2019 $0
2018 $
2017 $0
2016 $0
2015 $0
2014 $1
2013 $3
2012 $3
Intra-Cellular Therapies Quarterly Revenue
(Millions of US $)
2022-03-31 $35
2021-12-31 $26
2021-09-30 $22
2021-06-30 $20
2021-03-31 $16
2020-12-31 $12
2020-09-30 $7
2020-06-30 $2
2020-03-31 $1
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31
2015-12-31 $0
2015-09-30
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31
2012-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.497B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00